Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

275
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
275
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

635
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
635
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

511
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
511
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

445
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
445
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

608
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
608
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

274
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
274

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Virtual Screening and Biological Evaluation of Natural Products as Novel VPS34 Inhibitors that Modulate Autophagy.

ChemMedChem·2024
Same author

Overabundant endocannabinoids in neurons are detrimental to cognitive function.

bioRxiv : the preprint server for biology·2024
Same author

QBT improved cognitive dysfunction in rats with vascular dementia by regulating the Nrf2/xCT/GPX4 and NLRP3/Caspase-1/GSDMD pathways to inhibit ferroptosis and pyroptosis of neurons.

International immunopharmacology·2024
Same author

High salt condition alters LPS synthesis and induces the emergence of drug resistance mutations in <i>Helicobacter pylori</i>.

Antimicrobial agents and chemotherapy·2024
Same author

Free medial femoral condyle osteocutaneous flap for repairing stage IIIB osteonecrosis of the lunate: a case report.

BMC musculoskeletal disorders·2024
Same author

Preparation and Mechanism Analysis of High-Performance Humidity Sensor Based on Eu-Doped TiO<sub>2</sub>.

Sensors (Basel, Switzerland)·2024
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Sep 9, 2025

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.6K

La señalización endocannabinoide en la epilepsia

Chudai Zeng1, Chu Chen2

  • 1Department of Cellular and Integrative Physiology, Joe R. & Teresa Lozano Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, United States of America; Xiangya School of Medicine, Central South University, Changsha, Hunan 410011, China.

Neurobiology of disease
|August 31, 2025
PubMed
Resumen

El sistema endocannabinoide es prometedor para el tratamiento de la epilepsia al restaurar el equilibrio cerebral y reducir la inflamación. Dirigirse a este sistema ofrece una nueva esperanza para los pacientes con epilepsia resistente a los medicamentos.

Palabras clave:
2-araquidonilglicerol y sus derivadosReceptor de los cannabinoidesEndocannabinoides y sus derivadosLa epilepsiaLa monoacilglicerol lipasaLa neuroinflamaciónConfiscación

Más Videos Relacionados

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

2.6K
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.2K

Videos de Experimentos Relacionados

Last Updated: Sep 9, 2025

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.6K
Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

2.6K
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.2K

Área de la Ciencia:

  • La neurociencia
  • Farmacología

Sus antecedentes:

  • La epilepsia implica convulsiones recurrentes debido a la actividad neuronal anormal.
  • Los medicamentos anticonvulsivos existentes son ineficaces para muchos pacientes con epilepsia refractaria.
  • La neuroinflamación y la alteración del equilibrio excitatorio-inhibidor impulsan la epileptogénesis.

Objetivo del estudio:

  • Revisar el papel del sistema endocannabinoide (eCB) en la epilepsia.
  • Para explorar cómo la señalización eCB impacta la plasticidad neuronal y la inflamación.
  • Para resaltar el potencial terapéutico de dirigirse al sistema eCB para la epilepsia.

Principales métodos:

  • Revisión de los estudios preclínicos sobre la señalización eCB en la epilepsia.
  • Análisis de los mecanismos que regulan la plasticidad neuronal y la inflamación por los eCB.
  • Integración de las investigaciones actuales sobre la neuroprotección mediada por eCB.

Principales resultados:

  • El sistema eCB regula la homeostasis cerebral mediante la modulación de la transmisión sináptica y las respuestas inmunes.
  • La señalización eCB puede restaurar el equilibrio excitatorio-inhibidor y reducir la neuroinflamación.
  • La evidencia preclínica apoya los efectos anticonvulsivos y neuroprotectores de la orientación hacia el sistema eCB.

Conclusiones:

  • El sistema endocannabinoide presenta un objetivo terapéutico prometedor para la epilepsia.
  • La modulación de la señalización eCB ofrece un doble enfoque para reducir las convulsiones y la neuroinflamación.
  • La investigación adicional en terapias basadas en eCB podría conducir a nuevos tratamientos para la epilepsia refractaria.